# The Prelieve Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients

Study · id `cardio:ct-nct03030274` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03030274](<https://clinicaltrials.gov/study/NCT03030274>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03030274

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

## Technical summary

Registry record NCT03030274. Allocation not applicable; no masking; primary purpose treatment. Start 2017-10-11 (actual); primary completion 2021-05-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 106 participants (enrolled count; ClinicalTrials.gov record NCT03030274, source copy `cardio:ctgov-nct03030274-2022-09-15`, retrieved 2026-10-26)
- Started: 2017-10-11 (actual) (ClinicalTrials.gov record NCT03030274, source copy `cardio:ctgov-nct03030274-2022-09-15`, retrieved 2026-10-26)
- Primary completion: 2021-05-01 (actual) (ClinicalTrials.gov record NCT03030274, source copy `cardio:ctgov-nct03030274-2022-09-15`, retrieved 2026-10-26)
- Completion: 2022-03-02 (actual) (ClinicalTrials.gov record NCT03030274, source copy `cardio:ctgov-nct03030274-2022-09-15`, retrieved 2026-10-26)
- Countries: Belgium; Germany; Türkiye (ClinicalTrials.gov record NCT03030274, source copy `cardio:ctgov-nct03030274-2022-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03030274-2022-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Prelieve Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients
- Acronym: PRELIEVE
- Condition: Heart Failure Low Output
- Condition: Heart Failure
- Intervention (Device): Occlutech AFR device
- Lead sponsor: Occlutech International AB
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Occlutech International AB (`cardio:org-occlutech-international-ab`)

## Provenance

Content hash: 28b197e9ce68b9ca9b067a6d6f8a88b64e7c5a764093dab257681d95bc86a607
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
